Brand Name(s):Lucentis
Indication:Diabetic macular oedema
Choroidal neovascularisation (CNV)
Rationale:1,2
Considered:Oct-06
Review Date:Jan-22
Comments:
NICE technology appraisal guidance 274
1.1 Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if:
the eye has a central retinal thickness of 400 micrometres or more at the start of reatment and the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).
1.2 People currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.
Issued: February 2013
Further inforation available at: http://www.nice.org.uk/nicemedia/live/14082/62873/62873.pdf
…………………………
Ranibizumab for the treatment of diabetic macular oedema
Guidance
1. Ranibizumab is not recommended for the treatment of visual impairment due
to diabetic macular oedema.
2. People currently receiving ranibizumab for the treatment of visual impairment
due to diabetic macular oedema should have the option to continue treatment
until they and their clinicians consider it appropriate to stop.
NICE technology appraisal guidance 237 December 2011